FBG (mmol/L) · pre‐existing and new‐onset diabetes in kidney transplant recipients
1 finding from 1 review
Kidney function markers · pre‐existing and new‐onset diabetes in kidney transplant recipients
1 finding from 1 review
Death: unknown time frame · pre‐existing and new‐onset diabetes in kidney transplant recipients
It is very uncertain whether more intensive changes death (any cause) Time frame: 1 to 5 years compared with less intensive insulin therapy (very low certainty).
1 finding from 1 review
Hypoglycaemia · pre‐existing and new‐onset diabetes in kidney transplant recipients
1 finding from 1 review
Discontinuation of medication due to adverse events · pre‐existing and new‐onset diabetes in kidney transplant recipients
1 finding from 1 review
Hearing loss · children with cancer treated with platinum‐based therapy
Continuous platinum infusion showed no clear difference in hearing loss (asymptomatic and symptomatic disease according to… compared with bolus platinum infusion (low certainty).
1 finding from 1 review
Tinnitus ‐ not reported · children with cancer treated with platinum‐based therapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall survival ‐ not reported · children with cancer treated with platinum‐based therapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Event‐free survival · children with cancer treated with platinum‐based therapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Tumour response · children with cancer treated with platinum‐based therapy
1 finding from 1 review
no estimate extracted
1 study · 1 participants
Low
Adverse effects: toxic death (no definition provided) · children with cancer treated with platinum‐based therapy
Continuous platinum infusion showed no clear difference in adverse effects: toxic death (no definition provided) compared with bolus platinum infusion (low certainty).
1 finding from 1 review
Quality of life ‐ not reported · children with cancer treated with platinum‐based therapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality at 1 year · people with hepatocellular carcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life · people with hepatocellular carcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · people with hepatocellular carcinoma
1 finding from 1 review
Cancer‐related mortality at maximal · people with hepatocellular carcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Time to progression of the tumour · people with hepatocellular carcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Tumour response measures · people with hepatocellular carcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Non‐serious adverse events (hyperbilirubinaemia: most frequent) · people with hepatocellular carcinoma
1 finding from 1 review
Proportion of participants cleared or almost cleared ‐ · chronic palmoplantar pustulosis
It is very uncertain whether etretinate changes proportion of participants cleared or almost cleared in the short… compared with PUVA therapy (very low certainty).
1 finding from 1 review